Murine atopic dermatitis responds to peroxisome proliferator-activated receptors α and β/δ (but not γ) and liver X receptor activators

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 1-3, 2010, Pages

  Hatano, Yutaka ^a,c,d   Man, Mao Qiang ^a,c,e   Uchida, Yoshikazu ^a,c   Crumrine, Debra ^a,c   Mauro, Theodora M ^a,c   Feingold, Kenneth R ^a,b,c   Elias, Peter M ^a,c   Holleran, Walter M ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OITA UNIVERSITY   (Japan)

^e ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Atopic dermatitis; barrier function; liver X receptor; mouse model; peroxisome proliferator activated receptor , , and ; TH2 cells

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 22 HYDROXYCHOLESTEROL; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; CHEMOATTRACTANT; CIGLITAZONE; CLOBETASOL; CLOFIBRATE; GW 1514; HAPTEN; IMMUNOGLOBULIN E; INTERLEUKIN 1ALPHA; LIVER X RECEPTOR AGONIST; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIRINIXIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WY 16463; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CELL DENSITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; EOSINOPHIL; FEMALE; HAIRLESS MOUSE; HYDRATION; LYMPHOCYTE; MAST CELL; MOUSE; MURINAE; NONHUMAN; PRIORITY JOURNAL; STRATUM CORNEUM; TH2 CELL; THYMUS; TREATMENT OUTCOME;

EID: 73149125138     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.06.049     Document Type: Article

References (42)

1. Elias P.M., Wood L.C., and Feingold K.R. Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat 10 (1999) 119-126
2. Elias P.M., and Feingold K.R. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol 137 (2001) 1079-1081
3. Elias P., Wood L., and Feingold K. Relationship of the epidermal permeability barrier to irritant contact dermatitis. Immunol Allergy Clin North Am 17 (1997) 417-430
4. Taieb A. Hypothesis: from epidermal barrier dysfunction to atopic disorders. Contact Dermatitis 41 (1999) 177-180
5. Seidenari S., and Giusti G. Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol 75 (1995) 429-433
6. Sugarman J.L., Fluhr J.W., Fowler A.J., Bruckner T., Diepgen T.L., and Williams M.L. The objective severity assessment of atopic dermatitis score: an objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol 139 (2003) 1417-1422
7. Proksch E., Jensen J.M., and Elias P.M. Skin lipids and epidermal differentiation in atopic dermatitis. Clin Dermatol 21 (2003) 134-144
8. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., Zhao Y., Liao H., Lee S.P., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38 (2006) 441-446
9. Weidinger S., Illig T., Baurecht H., Irvine A.D., Rodriguez E., Diaz-Lacava A., et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 118 (2006) 214-219
10. Irvine A.D., and McLean W.H. Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. J Invest Dermatol 126 (2006) 1200-1202
11. Cork M.J., Robinson D.A., Vasilopoulos Y., Ferguson A., Moustafa M., MacGowan A., et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 118 (2006) 3-23
12. Ong P.Y., Ohtake T., Brandt C., Strickland I., Boguniewicz M., Ganz T., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347 (2002) 1151-1160
13. Patel T.S., Greer S.C., and Skinner Jr. R.B. Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. Am J Clin Dermatol 8 (2007) 189-194
14. Weischer M., Rocken M., and Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion?. Exp Dermatol 16 (2007) 385-393
15. Schmuth M., Jiang Y.J., Dubrac S., Elias P.M., and Feingold K.R. Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res 49 (2008) 499-509
16. Sheu M.Y., Fowler A.J., Kao J., Schmuth M., Schoonjans K., Auwerx J., et al. Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J Invest Dermatol 118 (2002) 94-101
17. Fowler A.J., Sheu M.Y., Schmuth M., Kao J., Fluhr J.W., Rhein L., et al. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Invest Dermatol 120 (2003) 246-255
18. Komuves L.G., Hanley K., Man M.Q., Elias P.M., Williams M.L., and Feingold K.R. Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPARalpha activators restores tissue homeostasis. J Invest Dermatol 115 (2000) 361-367
19. Man M.Q., Hatano Y., Lee S.H., Man M., Chang S., Feingold K.R., et al. Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol 128 (2008) 79-86
20. Choi E.H., Man M.Q., Wang F., Zhang X., Brown B.E., Feingold K.R., et al. Is endogenous glycerol a determinant of stratum corneum hydration in humans?. J Invest Dermatol 125 (2005) 288-293
21. Hachem J.P., Behne M., Aronchik I., Demerjian M., Feingold K.R., Elias P.M., et al. Extracellular pH Controls NHE1 expression in epidermis and keratinocytes: implications for barrier repair. J Invest Dermatol 125 (2005) 790-797
22. Demerjian M., Man M.Q., Choi E.H., Brown B.E., Crumrine D., Chang S., et al. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol 15 (2006) 154-160
23. Hou S.Y., Mitra A.K., White S.H., Menon G.K., Ghadially R., and Elias P.M. Membrane structures in normal and essential fatty acid-deficient stratum corneum: characterization by ruthenium tetroxide staining and x-ray diffraction. J Invest Dermatol 96 (1991) 215-223
24. Hachem J.P., Man M.Q., Crumrine D., Uchida Y., Brown B.E., Rogiers V., et al. Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. J Invest Dermatol 125 (2005) 510-520
25. Fartasch M. Epidermal barrier in disorders of the skin. Microsc Res Tech 38 (1997) 361-372
26. Chamlin S.L., Kao J., Frieden I.J., Sheu M.Y., Fowler A.J., Fluhr J.W., et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 47 (2002) 198-208
27. Cui C.Y., Kusuda S., Seguchi T., Takahashi M., Aisu K., and Tezuka T. Decreased level of prosaposin in atopic skin. J Invest Dermatol 109 (1997) 319-323
28. Kusuda S., Cui C.Y., Takahashi M., and Tezuka T. Localization of sphingomyelinase in lesional skin of atopic dermatitis patients. J Invest Dermatol 111 (1998) 733-738
29. Higuchi K., Hara J., Okamoto R., Kawashima M., and Imokawa G. The skin of atopic dermatitis patients contains a novel enzyme, glucosylceramide sphingomyelin deacylase, which cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. Biochem J 350 suppl (2000) 747-756
30. Hara J., Higuchi K., Okamoto R., Kawashima M., and Imokawa G. High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol 115 (2000) 406-413
31. Hachem J.P., Houben E., Crumrine D., Man M.Q., Schurer N., Roelandt T., et al. Serine protease signaling of epidermal permeability barrier homeostasis. J Invest Dermatol 126 (2006) 2074-2086
32. Mao-Qiang M., Fowler A.J., Schmuth M., Lau P., Chang S., Brown B.E., et al. Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol 123 (2004) 305-312
33. Elias P., Hatano Y., and Williams M. Basis for the barrier abnormality in atopic dermatitis: "outside-inside-outside" pathogenic mechanisms. J Allergy Clin Immunol 121 (2008) 1337-1343
34. Staumont-Salle D., Abboud G., Brenuchon C., Kanda A., Roumier T., Lavogiez C., et al. Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 121 (2008) 962-968 e6
35. Mao-Qiang M., Feingold K.R., and Elias P.M. Inhibition of cholesterol and sphingolipid synthesis causes paradoxical effects on permeability barrier homeostasis. J Invest Dermatol 101 (1993) 185-190
36. Behshad R., Cooper K.D., and Korman N.J. A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis. Arch Dermatol 144 (2008) 84-88
37. Elias P.M., Hatano Y., and Williams M.L. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 121 (2008) 1337-1343
38. Elias P.M., and Steinhoff M. Outside-to-inside' (and now back to "outside") pathogenic mechanisms in atopic dermatitis. J Invest Dermatol 128 (2008) 1067-1070
39. Li M., Messaddeq N., Teletin M., Pasquali J.L., Metzger D., and Chambon P. Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin. Proc Natl Acad Sci U S A 102 (2005) 14795-14800
40. Wood L.C., Elias P.M., Sequeira-Martin S.M., Grunfeld C., and Feingold K.R. Occlusion lowers cytokine mRNA levels in essential fatty acid-deficient and normal mouse epidermis, but not after acute barrier disruption. J Invest Dermatol 103 (1994) 834-838
41. Hatano Y., Uchida Y., Man M., Crumrine D., Chang S., Mauro T., et al. Maintenance of a acidic stratum corneum prevents emergence of murine atopic dermatitis. J Invest Dermatol 129 (2009) 1824-1835
42. Elias P.M., Williams M.L., Holleran W.M., Jiang Y.J., and Schmuth M. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res 49 (2008) 697-714